Wall Street analysts monitoring Wave Life Sciences (NASDAQ: WVE) generally issue a consensus "Moderate Buy" rating, with average 12-month price targets spanning significantly higher than current trading levels. Bullish analysts highlight its innovative PRISM RNA medicines platform and promising genetic pipeline candidates, while risk-tolerant investors weigh early-stage clinical volatility and biotech sector dynamics.